Oncophage approved in Russia for kidney cancer
NEW YORK-Antigenics Inc.’s personalized cancer vaccine Oncophage (vitespen) has received its first government approval.
NEW YORK-Antigenics Inc.’s personalized cancer vaccine Oncophage (vitespen) has received its first government approval. The Russian Ministry of Public Health has certified its use in kidney cancer patients at intermediate risk for disease recurrence, based on data from 604 patients showing a significant improvement in recurrence-free survival with Oncophage vs observation.
Derived from each individual’s tumor, Oncophage contains the “antigenic fingerprint” of the patient’s particular cancer and is designed to reprogram the body’s immune system to target only cancer cells bearing this fingerprint.
Articles in this issue
Immunotherapy agent promising in NSCLC
NCCN greenlights nilotinib for imatinib-resistant CML patients
No overall survival benefit for dose-intense regimen in SCLC
Make a note of new smoking cessation codes
Relistor for treating OIC
Experts argue against need for phase III proton Rx trials
Spotlight on Cancer Centers
Novel peptide vaccine promising in myeloid leukemia
Masters of hematology and oncology: Father of tamoxifen a Brit to the core
Intensive imatinib/chemo ups EFS in pediatric Ph+ ALL
Relapsing DLBCL patients respond to rituximab-based Rx
Who’s News
From the Editor
New compound inhibits Src family kinases
Are two binding sites better than one?
Recent Videos
Related Content
